BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 34289753)

  • 1. Therapeutic potential of biologics in prurigo nodularis.
    Müller S; Bieber T; Ständer S
    Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
    Müller S; Zeidler C; Ständer S
    Am J Clin Dermatol; 2024 Jan; 25(1):15-33. PubMed ID: 37717255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical evaluation of nemolizumab for prurigo nodularis.
    Brooks SG; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Prurigo.
    Thünemann J; Müller S; Steinbrink K; Ständer S; Zeidler C
    J Dtsch Dermatol Ges; 2024 Jun; 22(6):813-823. PubMed ID: 38722190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of dupilumab for adult patients with prurigo nodularis.
    Biazus Soares G; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
    Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
    Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
    Nilforoushzadeh MA; Heidari N; Ghane Y; Heidari A; Hajikarim-Hamedani A; Hosseini S; Jaffary F; Najar Nobari M; Tavakolzadeh P; Najar Nobari N
    Inflammopharmacology; 2024 Apr; 32(2):991-1003. PubMed ID: 38332383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
    Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
    J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.
    Frølunde AS; Wiis MAK; Ben Abdallah H; Elsgaard S; Danielsen AK; Deleuran M; Vestergaard C
    Dermatology; 2022; 238(5):950-960. PubMed ID: 35417906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
    N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulating Agents as Antipruritics.
    Erickson S; Nahmias Z; Rosman IS; Kim BS
    Dermatol Clin; 2018 Jul; 36(3):325-334. PubMed ID: 29929604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and treatment algorithm for chronic nodular prurigo.
    Ständer HF; Elmariah S; Zeidler C; Spellman M; Ständer S
    J Am Acad Dermatol; 2020 Feb; 82(2):460-468. PubMed ID: 31310842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
    Liao V; Cornman HL; Ma E; Kwatra SG
    Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of dupilumab in prurigo nodularis in elderly patient.
    Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
    Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
    Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806
    [No Abstract]   [Full Text] [Related]  

  • 18. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
    Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis.
    Alkon N; Assen FP; Arnoldner T; Bauer WM; Medjimorec MA; Shaw LE; Rindler K; Holzer G; Weber P; Weninger W; Freystätter C; Chennareddy S; Kinaciyan T; Farlik M; Jonak C; Griss J; Bangert C; Brunner PM
    J Allergy Clin Immunol; 2023 Aug; 152(2):420-435. PubMed ID: 37210042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab for the Treatment of Prurigo Nodularis.
    Alkhaleefa A; Woo TE; Parsons L
    Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.